Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

Michael Camilleri, E. A. Mayer, D. A. Drossman, A. Heath, G. E. Dukes, D. McSorley, S. Kong, A. W. Mangel, A. R. Northcutt

Research output: Contribution to journalArticle

331 Citations (Scopus)

Abstract

Background: No currently available treatment provides consistent relief of irritable bowel syndrome. Colonic sensory and motor function are modulated partly through 5HT3-receptors. Aim: To evaluate effects of the 5HT3-receptor antagonist, alosetron, in irritable bowel syndrome. Methods: Randomized, double-blind, placebo-controlled, dose-ranging (1, 2, 4, 8 mg b.d. alosetron), 12-week trial in 370 patients with diarrhoea-predominant or alternating constipation and diarrhoea irritable bowel syndrome. Weekly measurement of adequate relief was the key endpoint: other irritable bowel syndrome symptoms were collected daily using an electronic phone system. Results: Alosetron (1 mg or 2 mg b.d.) significantly (P <0.05 vs. placebo) increased the proportion of females, but not males, reporting adequate relief. Stool consistency, frequency and percentage days with urgency improved over placebo (P <0.05) within the first month with all doses of alosetron, and persisted throughout the trial with all doses in female patients. With 1 mg b.d. alosetron, females had improved stool consistency and urgency within the first week, and adequate relief and improved stool frequency within the first 2 weeks. There was no consistent improvement in bowel function among male patients. Conclusion: In female irritable bower syndrome patients with predominant diarrhoea or alternating constipation and diarrhoea, alosetron is effective in treatment of abdominal pain and discomfort and bowel-related symptoms.

Original languageEnglish (US)
Pages (from-to)1149-1159
Number of pages11
JournalAlimentary Pharmacology and Therapeutics
Volume13
Issue number9
DOIs
StatePublished - 1999

Fingerprint

Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Irritable Bowel Syndrome
Pain
Diarrhea
Placebos
Constipation
Double-Blind Method
Abdominal Pain
alosetron
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. / Camilleri, Michael; Mayer, E. A.; Drossman, D. A.; Heath, A.; Dukes, G. E.; McSorley, D.; Kong, S.; Mangel, A. W.; Northcutt, A. R.

In: Alimentary Pharmacology and Therapeutics, Vol. 13, No. 9, 1999, p. 1149-1159.

Research output: Contribution to journalArticle

Camilleri, Michael ; Mayer, E. A. ; Drossman, D. A. ; Heath, A. ; Dukes, G. E. ; McSorley, D. ; Kong, S. ; Mangel, A. W. ; Northcutt, A. R. / Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. In: Alimentary Pharmacology and Therapeutics. 1999 ; Vol. 13, No. 9. pp. 1149-1159.
@article{c3a2d2f77a6745cda528b867a9893970,
title = "Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist",
abstract = "Background: No currently available treatment provides consistent relief of irritable bowel syndrome. Colonic sensory and motor function are modulated partly through 5HT3-receptors. Aim: To evaluate effects of the 5HT3-receptor antagonist, alosetron, in irritable bowel syndrome. Methods: Randomized, double-blind, placebo-controlled, dose-ranging (1, 2, 4, 8 mg b.d. alosetron), 12-week trial in 370 patients with diarrhoea-predominant or alternating constipation and diarrhoea irritable bowel syndrome. Weekly measurement of adequate relief was the key endpoint: other irritable bowel syndrome symptoms were collected daily using an electronic phone system. Results: Alosetron (1 mg or 2 mg b.d.) significantly (P <0.05 vs. placebo) increased the proportion of females, but not males, reporting adequate relief. Stool consistency, frequency and percentage days with urgency improved over placebo (P <0.05) within the first month with all doses of alosetron, and persisted throughout the trial with all doses in female patients. With 1 mg b.d. alosetron, females had improved stool consistency and urgency within the first week, and adequate relief and improved stool frequency within the first 2 weeks. There was no consistent improvement in bowel function among male patients. Conclusion: In female irritable bower syndrome patients with predominant diarrhoea or alternating constipation and diarrhoea, alosetron is effective in treatment of abdominal pain and discomfort and bowel-related symptoms.",
author = "Michael Camilleri and Mayer, {E. A.} and Drossman, {D. A.} and A. Heath and Dukes, {G. E.} and D. McSorley and S. Kong and Mangel, {A. W.} and Northcutt, {A. R.}",
year = "1999",
doi = "10.1046/j.1365-2036.1999.00610.x",
language = "English (US)",
volume = "13",
pages = "1149--1159",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

AU - Camilleri, Michael

AU - Mayer, E. A.

AU - Drossman, D. A.

AU - Heath, A.

AU - Dukes, G. E.

AU - McSorley, D.

AU - Kong, S.

AU - Mangel, A. W.

AU - Northcutt, A. R.

PY - 1999

Y1 - 1999

N2 - Background: No currently available treatment provides consistent relief of irritable bowel syndrome. Colonic sensory and motor function are modulated partly through 5HT3-receptors. Aim: To evaluate effects of the 5HT3-receptor antagonist, alosetron, in irritable bowel syndrome. Methods: Randomized, double-blind, placebo-controlled, dose-ranging (1, 2, 4, 8 mg b.d. alosetron), 12-week trial in 370 patients with diarrhoea-predominant or alternating constipation and diarrhoea irritable bowel syndrome. Weekly measurement of adequate relief was the key endpoint: other irritable bowel syndrome symptoms were collected daily using an electronic phone system. Results: Alosetron (1 mg or 2 mg b.d.) significantly (P <0.05 vs. placebo) increased the proportion of females, but not males, reporting adequate relief. Stool consistency, frequency and percentage days with urgency improved over placebo (P <0.05) within the first month with all doses of alosetron, and persisted throughout the trial with all doses in female patients. With 1 mg b.d. alosetron, females had improved stool consistency and urgency within the first week, and adequate relief and improved stool frequency within the first 2 weeks. There was no consistent improvement in bowel function among male patients. Conclusion: In female irritable bower syndrome patients with predominant diarrhoea or alternating constipation and diarrhoea, alosetron is effective in treatment of abdominal pain and discomfort and bowel-related symptoms.

AB - Background: No currently available treatment provides consistent relief of irritable bowel syndrome. Colonic sensory and motor function are modulated partly through 5HT3-receptors. Aim: To evaluate effects of the 5HT3-receptor antagonist, alosetron, in irritable bowel syndrome. Methods: Randomized, double-blind, placebo-controlled, dose-ranging (1, 2, 4, 8 mg b.d. alosetron), 12-week trial in 370 patients with diarrhoea-predominant or alternating constipation and diarrhoea irritable bowel syndrome. Weekly measurement of adequate relief was the key endpoint: other irritable bowel syndrome symptoms were collected daily using an electronic phone system. Results: Alosetron (1 mg or 2 mg b.d.) significantly (P <0.05 vs. placebo) increased the proportion of females, but not males, reporting adequate relief. Stool consistency, frequency and percentage days with urgency improved over placebo (P <0.05) within the first month with all doses of alosetron, and persisted throughout the trial with all doses in female patients. With 1 mg b.d. alosetron, females had improved stool consistency and urgency within the first week, and adequate relief and improved stool frequency within the first 2 weeks. There was no consistent improvement in bowel function among male patients. Conclusion: In female irritable bower syndrome patients with predominant diarrhoea or alternating constipation and diarrhoea, alosetron is effective in treatment of abdominal pain and discomfort and bowel-related symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0032848856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032848856&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.1999.00610.x

DO - 10.1046/j.1365-2036.1999.00610.x

M3 - Article

C2 - 10468696

AN - SCOPUS:0032848856

VL - 13

SP - 1149

EP - 1159

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -